Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?-Reference-Cited by-同舟云学术

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Published:2017-08-01 Issue:59 Volume:8 Page:100863-100898
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Chae Young Kwang¹²³,Arya Ayush²,Chiec Lauren²,Shah Hiral¹,Rosenberg Ari²,Patel Sandip⁴,Raparia Kirtee²³,Choi Jaehyuk²³,Wainwright Derek A.²³,Villaflor Victoria¹²³,Cristofanilli Massimo¹²³,Giles Francis¹²³

Affiliation:

1. Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA

2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

3. Northwestern University Feinberg School of Medicine, Chicago, IL, USA

4. University of California San Diego, San Diego, CA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering immunohistochemistry in lung cancer;Critical Reviews in Oncology/Hematology;2024-08

2. PhiHER2: phenotype-informed weakly supervised model for HER2 status prediction from pathological images;Bioinformatics;2024-06-28

3. European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development;Toxicologic Pathology;2023-04

4. Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout;Archives of Pathology & Laboratory Medicine;2022-04-26

5. Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis;BMJ Open;2022-04